Indeed, it has been demonstrated that silencing of SREBP-1 caused a decrease in SREBP-1 downstream lipogenic genes, including FASN, inhibition of cell growth and aggressive behaviors, and induction of programmed death in PCa [23], endometrial [24], and ovarian [25] cancer cells. The gene discussed is FASN; the disease is posterior cortical atrophy.